Member Info for ChasPB

How will we know when the current round of Vaccines (1 &/or 2) have worn off of a person and therefore stopped providing protection?

Would a different Vaccine provide Longer (or Shorter) Protection?

I'm guessing that as we hear about more and more Variants, the current Vaccines will all need to be adapted, so will future Jabs be Multiple (or Combined (as MMR)) to offer maximum protection?

Will this be another phase of testing to be considered before Administering Jabs next Winter onwards?

Any of the Vaccines are 10/12/15 months protection yet?

How do they find out? Testing? When (6 months after 2nd dose?)

Suspect as we have many different Ages, many different Vaccines, many different Variants Testing will start Q3 onwards

Be Nice to know what is happening at the French Boarders.

As these are mainly closed (?} what checks if any are being made for: Eurostar/Euro Tunnel, Cargo Freight coming into Dover, Folkestone, Harwich, Newhaven ETC as well as Airlines/Motorways into Belgium, Holland, Germany, Switzerland.

[A year ago all the News clips showed everything being sprayed or disinfected, don't think I've seen anything related to this since last summer]

Is Novacyt/Primer Design PCR's being used yet, having a French office hopefully our products are being pushed?

DHSC contract - Phase 1
So possibly Phase 1 started in November through to February?, invoiced Monthly? and paid promptly the next month.
Therefore 1 payment received in Dec, and payments due Jan/Feb/Mar? How much?

This Phase 1 contract COULD possibly be extended? What could that be worth to us?

DHSC contract - Phase 2
Possibly be awarded to us (In FULL or In Part?) What could that be worth to us?

We have UNICEF/Ukraine contracts worth £13.5m from January 21

We are in for the Tender Bids totalling £22B, to be announced soon.

We have just announced launch of our PCR tests / PROmate / Winterplex and our Global customer base is 130 countries+

OH Yes, We have £90m in Bank, No debts, Purchased IT-IS, and have bought a Mountain of Materials for our Test Kits.

2 Further areas (Liverpool & Bristol) now reporting African Variant Cases.

Too many people doing too much travelling around the country for this to stop spreading across county lines.

A NEW fund investing in NCYT?

Argenta-Fund - Actions Pharma-Chimie R Cap - 94,340shs (approx: £750,000)

https://www.morningstar.com/stocks/xfra/nyz/ownership
[Tab: Funds]

Perhaps the Govt should also use VERSALAB at these 8 locations to support the door-to-door testing

"" It has secured significant contracts with national governments, including two with the Department for Health and Social Care in the UK (DHSC), as well as with other national non-government organisations, for the supply of its COVID-19 products. ""
Phase1, still we believe has £100m - £150m yet to be invoiced/paid in 2021), but what is the 2nd "Significant" other one with DHSC mentioned in extract from RNS above please?

And Remember, at last half year's average Cash figures:

We have already banked £37m in January + UNICEF/Ukraine contracts + ???

[Ref: Kat Hassard - Thx]

Updated #numis broker note - 29th January 2021

https://twitter.com/Kat_Hassard/status/1355454712926138368/photo/1

Ok, so perhaps only Nov invoice issued in 2020 & Dec/Jan/Feb invoices in 2021

And if we only have invoiced for Nov & Dec in 2020? perhaps 50% still Outstanding?

Do we invoice in Advance or Month End? Do we give them 30/60 days to pay? If so, Dec may have been paid Jan.

So I wonder how much revenue for Phase I was actually received by Y/End 2020?
and
How much Balance is still left to pay?

Although NCYT's figures were slightly better than Broker forecasts could it just be the Balance of Payments for this contract that could change peoples perception of GOOD to GREAT?

Now add in Januarys Contracts of UNICEF and Ukraine of (£22m) + Phase I = Fantastic "Start" to 2021

Revenue of €239.2 million (£213.7 million) delivered in H2 2020 compared to €72.4 million (£63.3 million) in H1 2020
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

So at current levels we are Banking £1.17m per day (£213.7m/182)

We will have New Products, New Services, New Contracts to ADD to this figure throughout 2021 and beyond.

Just need to "UP" the communication levels (especially detailed content) and (for me) improve the Companies Website

Remember, this time last year we were the equivalent of a "Start UP" company in the COVID world.

Between March and December we've come a really long way (£280m revenue) and more to come

"What’s happened to the nhs £469M contract ?"
---------------------------------------------------------------

So I'm guessing that only some of this contract was paid to us in 2020, with the balance being paid this Spring?

And the full amount is therefore NOT included in the Revenue Figures?

So this year (a FULL Year of production/Sales) should be MEGA !!!

" Therefore H2 2020 EBITDA above £143 million, = £785,000 / day = current rate of Earnings before Interest, Tax, Depreciation & Amortisation"

2021: we will have a FULL YEAR of Earnings, and just staying at these rates will = £286 million (v £187 million 2020)

and I think that is the minimum we will earn.

Does these figures make us even more attractive for a Takeover offer???

FOMO - How long to take action?

Maybe as little as 15 minutes if a 16:00 ~RNS
or 45 mins if a 16:30 or 07:00 9Fri) ~RNS

FRANCE - NOW €12.16 - Moving Back up - News imminent???

Being reported/commented on:
https://www.boursorama.com/bourse/forum/1rPALNOV/detail/457162743/

[ ## You may need to use TRANSLATE ##]

FSBio has partnered with Primer Design (a Novacyt group company) to support the scientific community's testing efforts.

Primer Design is a global leader in the manufacture of qPCR tests and, during the pandemic, distributed millions of COVID19 tests in over 230 countries

We bring to the United States the genesig COVID19 FDA-EUA test, a kit with comprehensive benefits to improve logistics and lab workflow by providing 100% specificity, among other key features we share as follows:

100% detection profile - genesig COVID19 detects all published strains from the RdRP region (ORF1ab gene)
Ongoing surveillance program - a team of bioinformaticians analyze virus sequences released daily to ensure that this 100% detection profile is maintained.